retatrutide phase 2 trial obesity nejm 2023 Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks Retatrutide Results: 24% Weight Loss

Currency volatility and lower health-care spend slow penetration, yet IDFs prevalence forecast suggests eventual policy shifts once biosimilar prices sink

Potential Side Effects of GLP-1 Medications: Gastrointestinal discomfort including constipation, diarrhea, nausea, and indigestion Loss of bone density and/or strength, loss of muscle mass and energy Inadequate nutrition intake from foods Key Considerations for GLP-1 Therapy Support: Ensure adequate Calcium, Magnesium, Vitamin K, and Vitamin D intake to maintain strong and healthy bones.* Prevent muscle loss by adding Protein, Amino Acids and other exercise support supplements into your routine.* Low energy levels may occur during GLP-1 therapy

10.1136/bmj.326.7404.1427 [DOI] [PMC free article] [PubMed] [Google Scholar] 58

10.2174/1386207325666220726163514 Comb

This network connects the ventral tegmental area (VTA) to the nucleus accumbens and is responsible for the hit of pleasure you feel when eating something delicious, receiving good news, or critically consuming alcohol or other addictive substances

[DOI] [PMC free article] [PubMed] [Google Scholar] 79.Han S, Mallampalli RK